Digi International Bolsters Digi Connect EZ Family of Device Servers with Launch of 8/16/32 Port Options
6.4.2023 15:00:00 EEST | Business Wire | Press release
Digi International, (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the launch of Digi Connect® EZ 8/16/32. This solution represents the latest in Digi’s line of next-generation device servers providing secure, scalable connectivity for business, commercial, and industrial automation applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005005/en/
Digi Connect EZ 8/16/32 comes with a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support. (Photo: Business Wire)
The product expansion underscores Digi’s commitment to supporting critical industries spanning utilities, energy, aerospace, government, commercial, logistics and factory automation with intelligent end-to-end serial connectivity solutions. Combining state-of-the-art hardware with the robust Digi Accelerated Linux (DAL) operating system, the Digi Connect EZ 8/16/32 line offers a range of industry-leading features. These include cellular support and the unparalleled central management capabilities of Digi Remote Manager® (Digi RM). This platform enables in-depth, 360-degree visibility to configure, deploy, and manage remote assets securely.
Also included with Digi Connect EZ 8/16/32 is a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support.
“We are excited to expand the Digi Connect EZ family, providing enhanced solutions and devices that enable our customers to conveniently and securely scale their operations today, while preemptively addressing the IIoT challenges of tomorrow,” said Brian Kirkendall, General Manager and Vice President of Infrastructure Management at Digi. “The incorporation and availability of our wider product features such as cellular support, central management with Digi RM, and round-the-clock expert assistance underscore Digi’s ongoing commitment to supporting customers throughout the entire product lifecycle.”
Hardware-enabled and software-defined, the Connect EZ family of products delivers a scalable solution that supports multiple serial interfaces in both industrial and non-industrial environments. Digi Connect EZ prevents data loss, providing state of the art communication technology to meet the needs of machine-to-machine serial communication customers all over the world. Additionally, the Connect EZ family offers an updated hardware platform that ensures longevity, manageability, and deployment flexibility. To manage critical serially connected equipment at scale, the Connect EZ family adheres to the following key attributes:
- Scalability — Simple click-to-connect deployment using Digi Navigator, with quick configuration providing easy integration for a wide range of use cases. Digi Connect EZ is truly easy to deploy and manage at scale throughout the product lifecycle with robust security, management and device health capabilities.
- Reliability — Built on top of the Digi TrustFence® design architecture and DAL operating system, Digi Connect EZ is designed for deployment in industrial environments to offer a secure, stable, and resilient platform for mission-critical connectivity, including LTE and Wi-Fi.
- Capability — Supports a wide range of industry standard and device-specific protocols using serial tunneling, and TCP/UDP connections or Digi’s patented RealPort® COM port redirector for remote native COM port access. Additionally, the built-in Python environment enables application development and customization at the device level, including event-based programmability, data conversion and full control of device connections.
“No matter the industry, no matter the challenge — from industrial automation to large scale manufacturing to secure communication of critical data — we’ve got our customers covered,” Kirkendall continued. “With the Connect EZ 8/16/32 expansion, we’re delivering the scalable and secure end-to-end connectivity solution our customers not only need, but that they deserve.”
Availability
Digi Connect EZ® 8/16/32 devices are available for immediate purchase now.
Explore the solutions here:
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. We help our customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, we’ve helped our customers connect over 100 million things and growing. For more information, visit Digi's website at www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005005/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom